US 6,143,508 AGranted

Device and process for cell capture and recovery

AssigneeRhone-Poulenc Rorer Pharmaceuticals Inc.

InventorThomas B. Okarma

Life of this patent

Estimating the term…

Loading patent…

Abstract

Devices, processes and compositions are provided for effective separation of cells from a mixture of cells, where depletion or positive selection may be employed to provide a cellular population of interest. Of particular utility is the separation of cells from peripheral blood mononuclear cells, where members of the lymphoid or myeloid lineages may be isolated and used for research, diagnosis or therapy. Also of interest are cellular separation from bone marrow, tumor suspensions or lymphoid tissue suspensions, where cells can be isolated and used for a variety of purposes. The separated cells may be homogeneous, free of exogenous biologicals, viable, capable of replication and exhibit their full complement of biological activities. Multiple phenotypes can be captured simultaneously. Captured cells can be specifically activated with cytokines and antigens to provide cells which are MHC restricted and have antigen-specific effector functions.

Claims28

Dependent claims

A method for preparing a separated cell population from a mixture of cells, comprising:

(a) contacting said mixture of cells with a device comprising at least one, optically clear polystyrene film or sheet, internal to the device, having support having a plurality receptors covalently bound to both flat surfaces thereof, which device has the following properties:
(i) the covalent bonding is produced by derivatizing the benzene rings of polystyrene which is less than 0.5% crosslinked;
(ii) the receptors are at a density of between about 200 ng receptor per cm.sup.2 surface area and about 250 ng receptor per cm.sup.2 surface;
and
(iii) the receptors bind specifically to at least one cell-surface ligand,
said contacting being for sufficient time for cells bearing said ligand to bind specifically to said receptors on said flat surfaces, resulting in specifically bound cells and unbound cells;
(b) removing said unbound cells from said device without significantly disturbing the binding of said specifically bound cells to said surface such that said bound cells remain bound to said device;
and
(c) releasing said bound cells from said device such that released cells are free of said receptors,
thereby preparing said separated cell population.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application: 08/484,559Filed 7 Jun 1995 · continuation in part
Priority: 29 Jun 1989
Granted: 7 Nov 2000
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C12N 5/0087
Purging biological preparations of unwanted cells: purging against subsets of blood cells, e.g. purging alloreactive T cells
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/22
Characterised by the effect or the function of the cells: immunosuppressive or immunotolerising
A61K 40/416
Vertebrate antigens: antigens related to auto-immune diseases; Preparations to induce self-tolerance

Family

Serial374,091Parent of this continuation · filed 29 Jun 1989
Serial638,030Parent of this continuation · filed 2 Jan 1991
Serial785,222Parent of this continuation · filed 28 Oct 1991
Serial291,335Parent of this continuation-in-part · filed 17 Aug 1994
US 6,143,508 AThis patent

From the US filing history. Foreign family members aren’t listed.